Company intelligence / Profile preview
Angstrom Pharmaceuticals
Solana Beach, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Angstrom Pharmaceuticals was a privately held biotech company developing first-in-class proprietary peptide drugs for cancer and metastatic disease. Its lead product, the A6 peptide ("Oncoparalytic"), aimed to inhibit tumor metastasis by paralyzing cancer cells. The most advanced clinical program targeted chronic lymphocytic leukemia and small lymphocytic lymphoma with the drug "Angstrom6" targeting LYVE1. The company raised over $10M in funding but ceased operations after its programs were discontinued following Phase II trials.
- Therapeutic areas
- Oncology
- Modalities
- Peptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Angstrom Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angstrom Pharmaceuticals.